GLP-1 receptor agonists are highly effective at reducing body weight — but weight loss is not the same as fat loss. When the body loses weight rapidly, it loses a combination of fat tissue and lean mass, including muscle. For women, who face additional hormonal pressures on muscle preservation from their 30s onward, this distinction matters significantly. Understanding the body composition picture of GLP-1 treatment is essential to getting the most from it.

What GLP-1 medications actually do to body composition

Clinical trials on GLP-1 receptor agonists consistently show that weight reduction includes loss of both fat mass and lean mass. In the STEP 1 trial of semaglutide, analysis of body composition showed that approximately 39% of the total weight lost was lean mass — with the remainder being fat mass. The absolute fat loss was substantial, but the lean mass component is clinically important.

This is not unique to GLP-1 medications — significant calorie restriction through any means tends to result in some lean mass loss. However, the effectiveness of GLP-1 medications at reducing appetite and calorie intake means the caloric deficit can be large, and without deliberate intervention, lean mass loss follows.

For context: lean mass includes skeletal muscle, organ mass, bone, and water in body tissues. Skeletal muscle is the component of greatest clinical concern, both for metabolic health and functional capacity.

Why this is particularly important for women

Women face specific hormonal challenges around muscle preservation that make the lean mass picture more consequential:

Baseline muscle mass. Women typically have lower absolute skeletal muscle mass than men, meaning the same percentage loss translates to less reserve capacity. Functional consequences — strength, mobility, metabolic rate — can be felt at lower thresholds.

Oestrogen and muscle. Oestrogen has anabolic properties — it supports muscle protein synthesis and reduces muscle protein breakdown. As oestrogen declines in perimenopause and menopause, muscle preservation becomes harder without intervention. Women using GLP-1 medications during perimenopause or beyond face both the accelerated lean mass loss of GLP-1 use and the age-related muscle decline driven by falling oestrogen.

Metabolic rate. Skeletal muscle is the most metabolically active tissue in the body — it drives resting energy expenditure at a much higher rate than fat tissue. Losing muscle reduces resting metabolic rate, which can make maintaining weight loss more difficult after stopping medication, and can make the body more vulnerable to rebound weight gain.

Bone density interaction. Lean mass loss on GLP-1 is partly structural — not just muscle, but potentially bone mineral density, particularly in women with existing bone density risk (perimenopause, low calcium intake, limited sun exposure). Preliminary data on GLP-1 and bone density is mixed and this area is under active research.

How to protect lean mass on GLP-1 treatment

Two interventions are consistently supported by evidence:

Resistance training. This is the most important tool for preserving muscle during weight loss on any method, including GLP-1. Resistance training (weight lifting, bodyweight exercises, resistance bands) provides the mechanical stimulus that signals the body to maintain skeletal muscle even in a caloric deficit. Current guidance from Zoey's medical team strongly emphasises initiating or maintaining resistance training when starting GLP-1 treatment — not as an afterthought but as a concurrent strategy from day one.

The STEP-HFpEF trial and other recent analyses have begun to look at exercise-plus-GLP-1 combinations, with encouraging signals for improved body composition outcomes. More data is emerging in this area.

Adequate protein intake. Protein provides the amino acids needed for muscle protein synthesis. During significant calorie restriction — which GLP-1 medications facilitate — protein intake can fall simply because total food intake falls. Maintaining sufficient daily protein intake requires deliberate attention to food quality when overall volume is reduced.

Singapore-licensed dietitians working alongside medical weight management programmes typically recommend higher protein targets for women on GLP-1 — personalised to body weight and activity level. General guidance in this context typically suggests protein as a priority in every meal, with animal proteins (eggs, fish, poultry, dairy) or high-quality plant proteins forming the basis.

What this means for how you track progress

Body weight alone is not a sufficient measure of progress on GLP-1 treatment. A woman who loses 10kg but retains more muscle and loses more fat is in a substantially better metabolic position than one who loses 10kg with higher muscle loss. If possible, monitoring with body composition tools — DEXA scan (gold standard), InBody or similar bioimpedance scales — provides more useful data than scales alone.

When to speak to a doctor

If you are on or considering GLP-1 medication for weight management, ask your doctor about incorporating resistance training and protein targets into your treatment plan from the start. If you are in perimenopause or post-menopause, or have existing concerns about bone density, these should be part of your assessment conversation.

Frequently Asked Questions

Do GLP-1 medications cause muscle loss? Weight loss from GLP-1 medications includes loss of both fat mass and lean mass (including muscle). Analysis of the STEP 1 trial found that approximately 39% of weight lost was lean mass. This is comparable to other forms of significant caloric restriction but is important to address deliberately through resistance training and adequate protein intake.

How much protein should I eat on GLP-1? There is no single answer that applies to all women, as recommendations depend on body weight, activity level, and age. In general, a higher protein target than the baseline recommended daily allowance is appropriate during active weight loss on GLP-1 — your doctor or dietitian can provide a personalised target. As a starting point, many clinical programmes suggest prioritising protein at every meal and not allowing GLP-1-related reduced appetite to disproportionately reduce protein intake.

Is resistance training safe when I have nausea from GLP-1 medication? Nausea is most common in the early weeks of GLP-1 treatment during dose escalation and typically reduces over time. If nausea is limiting physical activity, discuss timing and intensity of exercise with your doctor. In most cases, moderate-intensity resistance training can be maintained even with some nausea — adjusting the timing of meals and exercise may help.

Zoey is a doctor-led telehealth platform for women's health in Singapore. Consultations with Singapore-licensed doctors available online. Treatments are prescription-only medicines (POMs) and require medical assessment.